CELMoDs – A Worthy Successor to REVLIMID?
What is Multiple myeloma and How is it to be treated? Multiple myeloma is a cancer of plasma cells, and it affects approximately 138,000 people worldwide. The multiple myeloma market is dominated by several drugs, with REVLIMID being the leading therapy. However, with the entry of CELMoDs , such as iberdomide, many believe that they could be a worthy successor to REVLIMID. Generic competition to REVLIMID REVLIMID, also known as lenalidomide, is one of the most widely prescribed drugs for multiple myeloma . However, the drug has faced significant competition in recent years, with the entry of generic versions in 2022. The introduction of generic REVLIMID has had a considerable impact on the multiple myeloma market , with many patients switching to cheaper alternatives. The arrival of CELMODS CELMoDs, or cereblon modulating drugs, are a new class of drugs that work in a similar way to REVLIMID. They are designed to modify the activity of cereblon, a protein that plays a crucial role